Cargando...
Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice
Conventional treatment of hemophilia A (HA) requires repetitive IV injection of coagulation factor VIII (FVIII). Subcutaneous administration of FVIII is inefficient because of binding to the extravascular matrix, in particular to phospholipids (PLs), and subsequent proteolysis. To overcome this, rec...
Gardado en:
| Publicado en: | Blood |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
American Society of Hematology
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7952839/ https://ncbi.nlm.nih.gov/pubmed/32877516 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020006468 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|